Rizatriptan: a new milestone in migraine treatment. Closing remarks.
Pascual
J
J
University Hospital Marqués de Valdecilla, Department of Neurology, Santander, Spain. pascualj@medi.unican.es
D002986:Clinical Trials as Topic; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*; D014363:Tryptamines
D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; C093622:rizatriptan